The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 22, 2022
Filed:
Apr. 23, 2021
Applicant:
Crispr Therapeutics Ag, Zug, CH;
Inventors:
Jonathan Alexander Terrett, Cambridge, MA (US);
Demetrios Kalaitzidis, Cambridge, MA (US);
Mary-Lee Dequéant, Cambridge, MA (US);
Zinkal Samir Padalia, Cambridge, MA (US);
Assignee:
CRISPR Therapeutics AG, Zug, CH;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0783 (2010.01); A61P 35/00 (2006.01); A61K 35/17 (2015.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 15/11 (2006.01); C07K 14/705 (2006.01); C07K 14/74 (2006.01); C12N 9/22 (2006.01); C12N 15/86 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0636 (2013.01); A61K 35/17 (2013.01); A61K 47/6849 (2017.08); A61K 51/1027 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70539 (2013.01); C07K 14/70578 (2013.01); C07K 16/2803 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/74 (2013.01); C07K 2317/76 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2310/20 (2017.05); C12N 2510/00 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/80 (2013.01);
Abstract
Provided herein, in some embodiments, are methods and compositions (e.g., cell compositions) for the treatment of cancer. The methods and compositions involve genetically engineered immune cells (e.g., T cells), in which the endogenous CD70 gene is disrupted by genetic editing, for example, the CRISPR/Cas9 gene editing technology.